CoChat
Sign Up
Cited by 152Neonatal and Maternal InfectionsBacterial Infections and VaccinesStreptococcal Infections and Treatments

Status of vaccine research and development of vaccines for GBS

Open access
Heath, Paul T.·2016·Vaccine
DOI 10.1016/j.vaccine.2015.12.072
Open this paper in CoChat — free accountOpen PDF

Abstract

Streptococcus agalactiae (group B streptococcus (GBS)) is the leading cause of neonatal sepsis and meningitis in many countries. Intrapartum antibiotic strategies have reduced the incidence of early-onset neonatal GBS in a number of countries but have had no impact on late onset GBS infection (LOD). In low/middle income settings, the disease burden remains uncertain although in several countries of Southern Africa appears comparable to or higher than that of high-income countries. As disease may be rapidly fulminating cases can be missed before appropriate samples are obtained and this may lead to underestimation of the true burden. Given the rapid onset and progression within hours of birth as well as the deficiencies in IAP strategies and absence of a solution for preventing LOD, it is clear that administration of a suitable vaccine in pregnancy could provide a better solution in all settings; it should also be cost effective. The current leading vaccine candidates are CPS-protein conjugate vaccines but protein-based vaccines are also in development and one has recently commenced clinical trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2015.12.072

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There are no licensed vaccines against E. coli or group B S. agalactiae.

    “There are no licensed vaccines against E. coli or group B S. agalactiae, despite these two pathogens being the major causes of bacterial meningitis in neonates.”

    From Global etiology of bacterial meningitis: A systematic review and meta-analysis. (2018) · cites this paper as [13]

    Section 2.1 describes GBS vaccines as being in clinical trials, and Section 3 describes GBS vaccine candidates still undergoing development and regulatory assessment. This supports the absence of a licensed GBS vaccine, but the paper does not address whether an E. coli vaccine is licensed. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Madhi SA, Radebe K, Crewe-Brown H, Frasch CE, Arakere G, Mokhachane M, et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann Trop Paediatr 2003;23(1):15-23.

Cited by

Sorted by citations

Related

Authors
Heath, P. T.
Affiliations
St George's, University of London (GB)
Corresponding author
Heath, Paul T.
ORCID
Heath, Paul T.
Venue
Vaccine
Publisher
Elsevier BV
Published
2016-06
Volume
34
Issue
26
Pages
2876-2879
ISSN
0264-410X (ISSN-L)
DOI
10.1016/j.vaccine.2015.12.072
OpenAlex
W2301165522
Cited by
152
References
38
Citations by year
2026: 2 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 9 · 2020: 39 · 2019: 18 · 2018: 19 · 2017: 29 · 2016: 3 · 2015: 2
FWCI
22.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Vaccine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Neonatal and Maternal Infections
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Streptococcal Infections and Treatments
Keywords
Streptococcus agalactiae, neonatal sepsis, neonatal meningitis, intrapartum antibiotic prophylaxis, vaccine development, protein-based vaccines, maternal immunization, disease burden, cost-effectiveness
MeSH terms
Neonatal Sepsis, Clinical Trials as Topic, Female, Humans, Infant, Newborn, Meningitis, Pregnancy, Streptococcal Infections, Streptococcus agalactiae, Vaccines, Conjugate, Streptococcal Vaccines, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review